Solvias opens CoE for biologics and cell & gene therapy in Research Triangle Park in US

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, has announced the opening of its cutting-edge Centre of Excellence (CoE) for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina, US. The new facility expands Solvias' global network of centres and reinforces its commitment to advancing transformative therapies for cancer and rare diseases.

Spanning 50,000 square feet, the new centre is Solvias' flagship North American site for large molecule analytical services designed to accelerate the development and commercialisation of innovative biologics. The facility will bring approximately 200 new jobs to the Raleigh-Durham area over the next three years and is being rolled out in two phases:

• Phase 1: A 20,000-square-foot space for cGMP release testing—featuring cell-based potency and molecular assays—operational immediately.
• Phase 2: An additional 30,000 square feet expected to open in July 2025, offering expanded capabilities for stability testing and advanced biophysical characterization.

Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new centre offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release.